Short report: Yellow fever vaccine seroconversion in travelers

American Journal of Tropical Medicine and Hygiene

Volumn 85, Issue 4, 2011, Pages 748-749

  Kay, Allison ^a   Chen, Lin H ^a,b   Sisti, Maggie ^c   Monath, Thomas P ^c  

^a MOUNT AUBURN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Xcellerex Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; YELLOW FEVER VACCINE; VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; FEMALE; FLAVIVIRUS INFECTION; FOLLOW UP; HUMAN; MALE; SEROCONVERSION; TRAVEL; VACCINATION; YELLOW FEVER; ADOLESCENT; BLOOD; IMMUNOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; FEMALE; HUMANS; MALE; MIDDLE AGED; TRAVEL; YELLOW FEVER VACCINE; YOUNG ADULT;

EID: 80053923178     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2011.11-0363     Document Type: Article

References (14)

1. World Tourism Organization, 2010. UNWTO Tourism Highlights . Available at : www.unwto.org/facts/menu.html. Accessed March 28, 2011.
2. Monath TP, Cetron MS, 2002. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 34: 1369-1378. (Pubitemid 34507947)
3. Monath TP, Fowler E, Johnson C, Balser J, Morin M, Sisti M, Trent D, 2011. An inactivated cell-culture vaccine against yellow fever. N Engl J Med 364: 1326-1333.
4. Hepburn MJ, Kortepeter MG, Pittman PR, Boudreau EF, Mangiafico JA, Buck PA, Norris SL, Anderson EL, 2006. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine 24: 2843-2849.
5. Wisseman CL Jr, Sweet BH, Kitaoka M, Tamiya T, 1962. Immunological studies with group B arthropod-borne viruses. I. Broadened neutralizing antibody spectrum induced by strain 17D yellow fever vaccine in human subjects previously infected with Japanese encephalitis virus. Am J Trop Med Hyg 11: 550-561.
6. Monath TP, 1971. Neutralizing antibody responses in the major immunoglobulin classes to YF 17D vaccination of humans. Am J Epidemiol 93: 122-129.
7. Spector S, Tauraso NM, 1968. Yellow fever virus. I. Development and evaluation of a plaque neutralization test. Appl Microbiol 16: 1770-1775.
8. Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, Shope RE, Thomas N, Schrader R, Furby D, Bedford P, 2002. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 66: 533-541.
9. Lang J, Zuckerman J, Clarke P, Barrett P, Kirkpatrick C, Blondeau C, 1999. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am J Trop Hyg 60: 1045-1050. (Pubitemid 29296235)
10. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K, 1981. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59: 895-900. (Pubitemid 12155776)
11. Kayser M, Klein H, Paasch I, Pilaski J, Blenk H, Heeg K, 1985. Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine. J Med Virol 17: 35-45. (Pubitemid 15018991)
12. Rosenzweig EC, Babione RW, Wisseman CL Jr, 1963. Immunological studies with group B arthropod-borne viruses. IV. Per sistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. Am J Trop Med Hyg 12: 230-235.
13. Monath TP, Lee VH, Wilson DC, Fagbami A, Tomori O, 1974. Arbovirus studies in Nupeko Forest, a possible site of endemic yellow fever transmission in Nigeria. I. Serosurvey of humans and non-human primates. Trans R Soc Trop Med Hyg 68: 30-38.
14. Vinner L, Domingo C, Ostby AC, Rosenberg K, Fomsgaard A, 2011. Cases of travel-acquired dengue fever in Denmark 2001-2009. Clin Microbiol Infect Apr 5. doi: 10.1111/j.1469-0691 .2011.03543.x. [Epub ahead of print].